BioSpace News Archive

ICON plc, a world-leading healthcare intelligence and clinical research organisation, announced that Mr. Brendan Brennan, CFO of ICON plc, will present at:.

Pfizer Inc. announced the initiation of RENOIR, a Phase 3 clinical trial evaluating the efficacy, immunogenicity, and safety of a single dose of its respiratory syncytial virus bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 years or older.

TYME Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced that Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will present virtually at two upcoming healthcare conferences as follows:

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that Adam Grossman, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 12:30 p.m. ET.

TScan Therapeutics, Inc., a biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer, announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 4:15 p.m. ET.

OraSure Technologies, Inc., a global leader in point-of-care testing and sample collection technologies, announced that Chief Financial Officer Roberto Cuca has resigned from the Company effective September 17, 2021.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will be participating in the following upcoming investor conferences

Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced that members of its management team will participate in two upcoming virtual investor conferences.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in two upcoming healthcare investor conferences.